Genexine, Inc.

🇰🇷South Korea

Country: 🇰🇷South Korea

Ownership: Public

Established: 1999-06-08

Employees: 101

Market Cap: -

Website: http://www.genexine.com

Clinical Trials

Efficacy and Safety Study of GX-I7 Plus Adjuvant Temozolomide Combination in Patients With Newly Diagnosed Glioblastoma

Phase 1

Withdrawn

Conditions: Newly Diagnosed Glioblastoma

Interventions: Biological: GX-I7
Other: Placebo

First Posted Date: 2019-08-22

Last Posted Date: 2022-03-17

Lead Sponsor: Genexine, Inc.

Registration Number: NCT04065087

Locations: 🇰🇷
St. Vincent Hospital, Suwon-si, Korea, Republic of

A Phase 2, 12-Week, Double-Blind, Efficacy and Safety of GX-G6 in Patients With Uncontrolled Type 2 Diabetes Mellitus

Phase 2

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: GX-G6
Drug: Control

First Posted Date: 2019-05-23

Last Posted Date: 2019-05-23

Lead Sponsor: Genexine, Inc.

Target Recruit Count: 78

Registration Number: NCT03962010

Study of GX-I7 in Combination With Pembrolizumab in Refractory or Relapsed (R/R) TNBC Subjects(GX-I7-CA-006/KEYNOTE-899)

Phase 1

Completed

Conditions: Triple Negative Breast Cancer

Interventions: Drug: GX-I7
Drug: Pembrolizumab(KEYTRUDA®)
Drug: Cyclophosphamide

First Posted Date: 2018-11-26

Last Posted Date: 2024-03-05

Lead Sponsor: Genexine, Inc.

Target Recruit Count: 84

Registration Number: NCT03752723

Locations: 🇰🇷
Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Korea, Republic of
🇰🇷
Ewha Womans University Mokdong Hospital, Seoul, Korea, Republic of
🇰🇷
Gangnam Severance Hospital, Seoul, Korea, Republic of

and more 9 locations

GX-I7 With Cyclophosphamide in Patients With Metastatic or Recurrent Solid Tumors

Phase 1

Completed

Conditions: Solid Tumor

Interventions: Drug: GX-I7
Drug: Cyclophosphamide

First Posted Date: 2018-11-07

Last Posted Date: 2020-05-14

Lead Sponsor: Genexine, Inc.

Target Recruit Count: 24

Registration Number: NCT03733587

Locations: 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
🇰🇷
Seoul National University Bundang Hospital, Seongnam-si, Korea, Republic of

Safety and Tolerability of GX-G6 in Healthy Male Subjects

Phase 1

Completed

Conditions: Diabetes Mellitus

Interventions: Drug: Gx-G6
Drug: Placebo

First Posted Date: 2018-08-29

Last Posted Date: 2018-08-29

Lead Sponsor: Genexine, Inc.

Target Recruit Count: 48

Registration Number: NCT03651466

Locations: 🇩🇪
NUVISAN, Neu-Ulm, Germany

Dose-escalation Study to Evaluate the Safety and Tolerability of GX-I7 in Patients With Glioblastoma

Phase 1

Completed

Conditions: Newly Diagnosed Glioblastoma

Interventions: Drug: GX-I7

First Posted Date: 2018-08-07

Last Posted Date: 2020-11-10

Lead Sponsor: Genexine, Inc.

Target Recruit Count: 15

Registration Number: NCT03619239

Locations: 🇰🇷
The Catholic University of Korea Seoul St. Mary's Hospital, Seoul, Seocho, Korea, Republic of

Study to Evaluate Safety and Tolerability of GX-I7 in Patients With Locally Advanced or Metastatic Solid Tumors

Phase 1

Completed

Conditions: Locally Advanced or Metastatic Solid Tumors

Interventions: Drug: GX-I7

First Posted Date: 2018-03-27

Last Posted Date: 2020-05-11

Lead Sponsor: Genexine, Inc.

Target Recruit Count: 35

Registration Number: NCT03478995

Locations: 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
🇰🇷
Severance Hospital, Seoul, Korea, Republic of
🇰🇷
Seoul St. Mary's Hospital, of the Catholic University, Seoul, Korea, Republic of

The Combination of GX-188E Vaccination and Pembrolizumab in Patients With HPV 16 and/or 18+ Advanced Cervical Cancer

Phase 1

Completed

Conditions: Cervical Cancer

Interventions: Drug: GX-188E
Drug: KEYTRUDA®

First Posted Date: 2018-02-23

Last Posted Date: 2024-03-01

Lead Sponsor: Genexine, Inc.

Target Recruit Count: 65

Registration Number: NCT03444376

Locations: 🇰🇷
Inje University Busan Paik Hospital, Busan, Korea, Republic of
🇰🇷
Keimyung University Dongsan Medical Center, Daegu, Korea, Republic of
🇰🇷
Seoul National University Bundang Hospital, Gyeonggi-do, Korea, Republic of

and more 6 locations

Dose Finding Study of GX-H9 in Paeditaric Patients With Growth Hormone Deficiency

Phase 2

Completed

Conditions: Growth Hormone Deficiency

Interventions: Drug: GX-H9
Drug: Genotropin

First Posted Date: 2017-10-16

Last Posted Date: 2020-04-20

Lead Sponsor: Genexine, Inc.

Target Recruit Count: 56

Registration Number: NCT03309891

Locations: 🇺🇦
Odessa National Medical University, Odessa Regional Children's Hospital, Odessa, Ukraine

Tolerability, Safety and Pharmacokinetics Study of GX-30 in Total Thyroidectomy or Near Total Thyroidectomy Patients

Phase 1

Completed

Conditions: Total Thyroidectomy
Near-total Thyroidectomy

Interventions: Drug: Period 1 GX-30, Period 2 THYROGEN®
Drug: Period 1 THYROGEN®, Period 2 GX-30

First Posted Date: 2017-09-08

Last Posted Date: 2020-09-09

Lead Sponsor: Genexine, Inc.

Target Recruit Count: 8

Registration Number: NCT03276988

Locations: 🇰🇷
Pusan National University Hospital, Busan, Korea, Republic of
🇰🇷
Seoul Asan Medical Center, Seoul, Korea, Republic of
🇰🇷
Korea University Anam Hospital, Seoul, Korea, Republic of

and more 2 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy